These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35123640)

  • 41. Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro.
    Pang N; Duan X; Jiang M; Qu J; Yuan H; Xu J; Cao H; Chen G
    Int J Clin Exp Pathol; 2015; 8(8):8892-901. PubMed ID: 26464630
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons.
    Tremblay G; Tomaras D; Strati E; Forsythe A
    J Health Econ Outcomes Res; 2021 Feb; 8(1):10-17. PubMed ID: 33768123
    [No Abstract]   [Full Text] [Related]  

  • 43. Ruxolitinib Combined with Corticosteroids as First-Line Therapy for Acute Graft-versus-Host Disease in Haploidentical Peripheral Blood Stem Cell Transplantation Recipients.
    Hou C; Dou L; Jia M; Li F; Wang S; Gao X; Wang L; Jin X; Wang L; Gao C; Liu D
    Transplant Cell Ther; 2021 Jan; 27(1):75.e1-75.e10. PubMed ID: 32961370
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies.
    Zhao Y; Chen P; Dou L; Li F; Li M; Xu L; Chen J; Jia M; Huang S; Wang N; Luan S; Yang J; Bai N; Liu D
    Drug Des Devel Ther; 2022; 16():817-825. PubMed ID: 35370398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating CD14(+) HLA-DR(-/low) myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease.
    Yin J; Wang C; Huang M; Mao X; Zhou J; Zhang Y
    Cancer Med; 2016 Jul; 5(7):1654-69. PubMed ID: 27109254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bowel wall thickness is a strong predictor of steroid-refractory acute graft-versus-host disease with gut involvement after allo-HSCT.
    Drokov M; Yatsyk G; Kireeva A; Pirikova O; Dubnyak D; Kuzmina L; Vasilyeva V; Popova N; Starikova O; Parovichnikova E; Savchenko V
    Int J Hematol; 2022 Apr; 115(4):545-552. PubMed ID: 35098481
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
    Belina ME; Driscoll TA; Blanchard SK; Cardones AR
    Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Jabr R; El Atrouni W; Shune L; Telfah M; Gao G; He J; Abhyankar S; McGuirk J; Clough L
    Transplant Cell Ther; 2021 Feb; 27(2):176.e1-176.e8. PubMed ID: 33830032
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Steroid-refractory gastrointestinal acute graft-versus-host disease treated with vedolizumab and ruxolitinib in a pediatric patient with therapy-related acute myeloid leukemia].
    Nagasawa S; Yamada A; Kinoshita M; Kamimura S; Tanaka H; Nishikawa T; Okamoto Y; Moritake H
    Rinsho Ketsueki; 2023; 64(1):23-29. PubMed ID: 36775302
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
    PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of CD3+CD4-CD8- (double negative) T cells reconstitution in patients following hematopoietic stem-cell transplantation.
    Ye H; Chang Y; Zhao X; Huang X
    Transpl Immunol; 2011 Dec; 25(4):180-6. PubMed ID: 21911061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Reconstitution kinetics of T helper cells subsets post unmanipulated allogeneic blood and marrow transplantation].
    Zhao XY; Zhao XS; Wang YZ; Chang YJ; Lv M; Wang HT; Han TT; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):745-50. PubMed ID: 24103870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia.
    Zhang Y; Zheng H; Ren J; Luo X; Zheng Z; Zheng J; Zheng X; Chen Y; Chen Z; Hu J; Yang T
    Hematol Oncol; 2021 Aug; 39(3):380-389. PubMed ID: 33848027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Yang S; Wei Y; Sun R; Lu W; Lv H; Xiao X; Cao Y; Jin X; Zhao M
    Cytotherapy; 2020 Dec; 22(12):718-733. PubMed ID: 32811747
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.
    Yu J; Parasuraman S; Shah A; Weisdorf D
    Curr Med Res Opin; 2019 Jun; 35(6):983-988. PubMed ID: 30461314
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Low Level of Plasmacytoid Dendritic Cells at Engraftment Is a Valuable Prognostic Indicator in Children Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Li B; Meng L; Tian Y; Ling J; Hu Y; Lu Q; Gao L; Wu S; Zhang Y; Hu S
    Transplant Cell Ther; 2021 Jul; 27(7):611.e1-611.e12. PubMed ID: 33895404
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
    Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
    Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.